News

CRISPR Therapeutics Reveals Innovative Data at AHA 2025 Event

CRISPR Therapeutics Reveals Innovative Data at AHA 2025 Event

CRISPR Therapeutics Shows Groundbreaking Results at AHA 2025

CRISPR Therapeutics, a pioneering biopharmaceutical firm known for its innovative gene-editing solutions, has announced an exciting opportunity. During the upcoming American Heart Association (AHA) Scientific Sessions 2025, the company will present crucial findings from its Phase 1 clinical trial. This trial investigates the efficacy of CRISPR/Cas9 technology in addressing cardiovascular conditions.

Insights on CRISPR/Cas9 Gene Editing Therapy

The spotlight will be on CTX310™, an experimental gene therapy aimed at targeting angiopoietin-related protein 3 (ANGPTL3). This treatment is designed for combating cardiovascular and cardiometabolic diseases. The oral presentation will occur on November 8, 2025, at 8:30 a.m. CST, featuring an in-depth review of the trial results.

Focus on Another Key Therapy: CTX340™

Additionally, CRISPR Therapeutics will showcase CTX340™, which targets angiotensinogen (AGT) to address refractory hypertension. A poster presentation highlighting the preclinical program will be presented later that same day, providing further insights into the potential of gene editing in hypertension treatment strategies.

Important Session Details

Here are some key details regarding the presentations:

Abstract Title: First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Abstract Number: 4392851
Session Type: Late-Breaking Science (Oral Presentation)
Session Title: Groundbreaking Trials in Cardiometabolic Therapeutics
Session Date and Time: Saturday, November 8, 2025, 8:30 a.m. CST

Abstract Title: In vivo gene editing of Angiotensinogen in hepatocytes safely and potently reduces blood pressure in preclinical models
Abstract Number: 4391815
Session Type: Late-Breaking Basic Science (Poster Presentation)
Session Title: Precision Interventions for the Failing Heart: Genetic, Metabolic, and Immune Frontiers
Session Date and Time: Saturday, November 8, 2025, 2:30 p.m. CST

The Latest on CRISPR Therapeutics’ Advancements

CRISPR Therapeutics continues to strengthen its innovative portfolio. This biopharmaceutical company has enhanced its lipid nanoparticle (LNP) platform, enabling the efficient delivery of CRISPR/Cas9 therapies to the liver, which is crucial for treating cardiovascular issues. The lead programs, CTX310 and CTX320, are making progress in clinical trials focusing on familial hypercholesterolemia and related disorders.

Moreover, the company's R&D initiatives are not limited to CTX310 and CTX320. Other promising candidates include CTX340 and CTX450, which are being explored for their potential in targeting AGT for hypertension management and ALAS1 for acute hepatic porphyria, respectively. These programs signify the commitment CRISPR Therapeutics has toward pioneering treatments for serious ailments.

Milestones Achieved by CRISPR Therapeutics

Over the past decade, CRISPR Therapeutics has risen to prominence within the biotechnology sector. Its trajectory changed dramatically with the approval of the first-ever CRISPR-based therapy. The success of this innovative approach has opened doors for further exploration into genetic therapies aimed at treating a range of disorders like hemoglobinopathies, oncology, and autoimmune diseases.

The advancements underscore the company's dedication to delivering novel therapies that leverage groundbreaking CRISPR technology. As science continues to evolve, CRISPR Therapeutics remains committed to making strides towards effective solutions for complex medical challenges.

Contact Information for Investor and Media Inquiries

For those interested in learning more about CRISPR Therapeutics and its ongoing projects, the company provides dedicated contact resources:

Investor Contact:
+1-617-307-7503
ir@crisprtx.com

Media Contact:
+1-617-315-4493
media@crisprtx.com

Frequently Asked Questions

What is CRISPR Therapeutics focusing on at the AHA 2025?

CRISPR Therapeutics will present findings related to its Phase 1 clinical data for gene editing therapies addressing cardiovascular diseases.

What are CTX310 and CTX340?

CTX310 targets ANGPTL3 for heart diseases, while CTX340 focuses on reducing blood pressure by targeting angiotensinogen (AGT).

When will the presentations occur?

The oral presentation is scheduled for November 8, 2025, at 8:30 a.m. CST, followed by a poster presentation later the same day.

How long has CRISPR Therapeutics been in operation?

Founded over a decade ago, CRISPR Therapeutics specializes in developing CRISPR-based genetic therapies.

How can I contact CRISPR Therapeutics for inquiries?

Investors can reach out via +1-617-307-7503 or ir@crisprtx.com for investment-related questions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

Updated Category News Views 0

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Continue Reading
Maurices Strengthens Position with Key Refinancing Deal

Updated Category News Views 2

Maurices' Bold Financial Maneuver When a retailer like Maurices, with its near-century-long history, decides to play in the financial arena, it sure makes my ears perk up. This Duluth-based women's fashion retailer isn't just dipping its toes in—it's executing a full-blown refinancing blitzkrieg and coming out stronger. Announcing the completion of its refinancing plan...

Continue Reading
Facility Solutions Group Climbs to Top 18 Electrical Spot

Updated Category News Views 1

FSG Shines Brightly in Electrical Contractor Rankings Climbing the ladder is no easy feat, but Facility Solutions Group (FSG) has managed to climb, all the way to the #18 spot on Electrical Construction & Maintenance (EC&M) magazine's revered list of the Top Electrical Contractors in the U.S. It’s up from their previous rank of 22. When you think about the competitive...

Continue Reading
Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Updated Category News Views 1

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...

Continue Reading
Give Lively & Change Simplify CA Nonprofit Compliance

Updated Category News Views 0

A Fresh Wind Blowing for California Nonprofits So, here's a twist in the nonprofit world that's stirring the pot just right. Give Lively and Change have partnered up to tackle the thorny issue of regulatory compliance in California. It's a big win for the nonprofits looking to keep fundraising through Give Lively without getting tangled in the bureaucratic web spun up by...

Continue Reading
MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Updated Category News Views 3

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

Continue Reading
South Florida Donor Network Honors 52 Heroic Donors

Updated Category News Views 3

A Heartfelt Tribute to Lifesavers You ever been to a gathering that reminds you how deeply human connections run? That's what happened at The Diplomat Beach Resort in Hollywood. South Florida Donor Network (SFDN) pulled together a ceremony honoring 52 donor heroes whose legacies beat strong through the recipients living thanks to their gifts. An Event Worth Attending...

Continue Reading
Global Communication Works Opens SignlLabs™ AI Licensing

Updated Category News Views 38

AI Signaling Moves Beyond GCW's Own Clients Remember when we first looked at GCW's SignlLabs and the idea of helping brands show up inside ChatGPT, Gemini, Claude, Copilot and Perplexity? Well, Global Communication Works is taking the next step. Instead of keeping its AI Signaling playbook inside the agency walls, GCW is now opening SignlLabs up for licensing

Continue Reading
Wave Kids™ Unveils New Flavors for Kids' Drinks

Updated Category News Views 1

Sparking a Fresh Wave in the Kids' Beverage Market Alright, let me tell you about a new player plowing into the kids' drink scene. Wave Kids™, a brand that's making waves—pun intended—has a fresh lineup that screams 'fun' and 'healthy' in equal measure. Just coinciding with back-to-school season, this Scottsdale, Arizona outfit has rolled out not one or two, but...

Continue Reading
Woodpack Global Unveils Crate Design System: A New Era Begins

Updated Category News Views 1

Innovating the Wooden Crate Landscape An old industry got a much-needed facelift today, folks. Woodpack Global has rolled out Crate Design System™ (CDS)—a snazzy new tool that's shaking up the wooden crate design landscape. It blows the dust off outdated design methods that have been collecting cobwebs since the '60s. That's right, we’re talking about a significant...

Continue Reading

Top 5 Most Recently Viewed Articles

NXP Semiconductors Declares Exciting Q4 Interim Dividend

Updated Category News Views 114

NXP Semiconductors Declares Exciting Q4 Interim Dividend NXP Semiconductors N.V. (NASDAQ: NXPI), a major player in the semiconductor industry, recently made headlines by announcing an interim dividend of $1.014 per ordinary share for the fourth quarter. This declaration not only highlights the company’s robust financial position but also reflects the board’s...

Continue Reading
Bittensor's Price Surges 3% in Just 24 Hours' Trading

Updated Category News Views 60

Bittensor Sees Notable Price Increase Bittensor has experienced a remarkable price boost of 3.15% in the last 24 hours, bringing its current price to $287.79. Looking back over the past week, this cryptocurrency has surged by more than 20.0% from last week’s figure of $240.79. Investors are keenly observing Bittensor as it aims to reach its all-time high of $757.60....

Continue Reading
INEOS Quattro Finance 2 PLC Announces Cash Tender Offer Update

Updated Category News Views 148

INEOS Quattro Finance 2 PLC Reports Significant Tender Offer Results INEOS Quattro Finance 2 Plc, known for its innovative financing solutions, recently revealed the outcomes of its recent cash tender offer for its outstanding 3 3/8% Senior Secured Notes due 2026. This offer has drawn considerable attention, reflecting the company’s proactive approach to managing its...

Continue Reading
Brightstar Lottery PLC Preps for Q2 2026 Results Call

Updated Category News Views 11

Brightstar's Conference Call: Mark Your Calendars Alright, folks, Brightstar Lottery PLC, trading on the NYSE under the glitzy ticker BRSL, is gearing up to spill the beans on those coveted second-quarter numbers. It's all going down on August 4th—an 8:00 a.m. EDT start time, so don't be late to the party. And hey, make sure you pre-register, because getting caught...

Continue Reading
Celebrating Excellence: CPAmerica's Firms Shine in Rankings

Updated Category News Views 192

Five CPAmerica Firms Honored Among Top Tax and Accounting Firms Five member firms of CPAmerica have received prestigious recognition in the USA Today's inaugural list of the Top 100 Tax and Accounting Firms. This remarkable acknowledgment reflects the diligent efforts of these firms, which were chosen through thorough surveys conducted by an independent market research...

Continue Reading